Avoplacel is under clinical development by Pluri and currently in Phase I for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). According to GlobalData, Phase I drugs for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Avoplacel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Avoplacel overview
Avoplacel (PLXR-18) is under development for the treatment of acute radiation syndrome and incomplete hematopoietic recovery following bone marrow transplantation. The therapeutic candidate is an allogeneic product. The therapeutic candidate is administered through intramuscular route. It is developed based on a three-dimensional technology platform which enables the conversion of human placental cells into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues.
It was also under development for the treatment of chemotherapy induced bone marrow hypoplasia, and aplastic anemia.
Pluri overview
Pluri, formerly Pluristem Therapeutics is a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. The company’s placental expanded cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. Pluri’s product pipeline includes PLX-PAD for critical limb ischemia, intermittent claudication, orthopedic conditions, pulmonary arterial hypertension and women’s health. The company’s PLX-Immune for kidney, colorectal, breast, lung, muscle, skin and liver cancers, PLX-R18 for hematological system and acute radiation syndrome. Pluri harnesses its proprietary 3D cell expansion platform technology for developing its cell therapies. It works in partnership with medical, pharmaceutical and academic institutions. Pluri is headquartered in Haifa, Israel.
For a complete picture of Avoplacel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
